Evotec

RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations

Retrieved on: 
Tuesday, April 11, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Data management, Pancreatic cancer, PPD, Senior, Evotec, Good clinical data management practice, Controller, LAPC, Long-term care, Clinical trial, World Health Organization, Quality of life, Omnicare, Patient, Heel, Contract research organization, CFO, Clinical Systems and Networks, SVP, EVO, Bulletin, Pharmaceutical industry, IQVIA

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced today that Leesa Gentry has joined the Company as Senior Vice President of Clinical Operations.

Key Points: 
  • RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced today that Leesa Gentry has joined the Company as Senior Vice President of Clinical Operations.
  • Ms. Gentry, an industry expert in clinical trials management, brings the RenovoRx team valuable leadership experience to further advance studies in cancer treatment.
  • Prior to RenovoRx, she was Senior Vice President (SVP) of Clinical Operations at Evotec.
  • “Leesa is an outstanding clinical operations leader with decades of diverse experience that will make an immediate impact to enhance our clinical trials,” said RenovoRx CEO, Shaun Bagai.

KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING

Retrieved on: 
Tuesday, April 4, 2023
AT/RT, Tissue, Abstract, AACR, University, VEGFR3, Johns Hopkins School of Medicine, Overalls, Survival, Clinical trial, BRAF, Research, MEK, Brain, ACVR1, KZIA, Huntsman Cancer Institute, DIPG, MD, Patient, Melanoma, FDA, Gemcitabine, Institut Universitaire de France, Pharmaceutical industry, Medical imaging, Dentistry, Evotec, Kazia Pelka

In total, there will be five presentations at AACR, four of which build on previous positive data for paxalisib in melanoma and childhood brain cancer.

Key Points: 
  • In total, there will be five presentations at AACR, four of which build on previous positive data for paxalisib in melanoma and childhood brain cancer.
  • The new data being presented provide significant support and direction for the future development of paxalisib in these expansion indications.
  • In addition, a presentation by scientists from Kazia's partner, Evotec, will outline the novel biomarker strategy employed in the phase I study of EVT801, and anticipates the potential initial clinical data from EVT801 in CY2023.
  • This data expands on positive data for paxalisib as monotherapy and in other combination regimens that was presented at AACR in 2022.

EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership

Retrieved on: 
Tuesday, March 28, 2023
Partnership, Drug development, Senior, SALES, Neuroscience, Bristol Myers Squibb, Research, Doctor of Philosophy, BMY, Patient, Drug discovery, ISIN, Frankfurt Stock Exchange, BMS, FDA, IND, NYSE, EVO, MDAX, Sales, Pharmaceutical industry, Evotec

Based on this success, Bristol Myers Squibb and Evotec extend and expand this partnership for additional 8 years with the goal to further broaden and deepen the strategic alliance.

Key Points: 
  • Based on this success, Bristol Myers Squibb and Evotec extend and expand this partnership for additional 8 years with the goal to further broaden and deepen the strategic alliance.
  • Evotec and Bristol Myers Squibb (formerly “Celgene”) initiated the collaboration in 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases.
  • Richard Hargreaves, PhD, Senior Vice President Neuroscience at Bristol Myers Squibb, commented: “We are pleased to extend and expand our neuroscience drug development partnership with Evotec.
  • We look forward to continuing our drug discovery research into key mechanisms in neurodegeneration and delivering potential therapeutic candidates for patients who are suffering from these devastating diseases.”
    Dr Cord Dohrmann, Chief Scientific Officer of Evotec, added: “We are excited to expand our strategic neurodegeneration partnership with Bristol Myers Squibb.

EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year

Retrieved on: 
Tuesday, March 28, 2023
Database, Plague, Multiomics, Partnership, BofA Securities, Therapy, IPSC, Diabetes, Just, Clinical trial, Janssen, Type 1 diabetes, Almirall, USD, EDT, Eli Lilly, Projection, Boehringer Ingelheim, Neuroscience, PIN, EBITDA, Investment, DSM-IV codes, Medicine, Growth, CEST, Webcast, BMS, European Investment Bank, Annual report, Hand, GBP, Fine chemical, Pharmaceutical industry, Cryptocurrency, EU, Evotec, Ophthalmology

Growth of the base business was 30% from € 556.7 m in 2021 to € 725.5 m in 2022.

Key Points: 
  • Growth of the base business was 30% from € 556.7 m in 2021 to € 725.5 m in 2022.
  • In 2022, Evotec was involved in > 800 alliances and recorded a repeat business of 92%.
  • In September 2022, Evotec launched the construction of its second J.POD biologics manufacturing facility at Evotec’s Campus Curie in Toulouse.
  • The full annual report 2022 as well as the sustainability report 2022 will be available for download on 25 April.

EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis

Retrieved on: 
Friday, March 24, 2023
MDAX, United Nations Sustainable Development Group, Disability, SAFER, TB, Infection, Global health, HEALTH, BILL, UNIVERSAL, Drug resistance, Death, OF, Patient, Tuberculosis, UN, Drug discovery, ISIN, Frankfurt Stock Exchange, Bill, World Tuberculosis Day, Bill & Melinda Gates Foundation, EVO, Disease, Pharmaceutical industry, Evotec

The grant is the second award from the foundation to Evotec supporting TB drug discovery, and allows the Company to progress a portfolio of TB drug discovery projects that have the potential to contribute to a universal, shorter, safer and simpler TB drug regimen.

Key Points: 
  • The grant is the second award from the foundation to Evotec supporting TB drug discovery, and allows the Company to progress a portfolio of TB drug discovery projects that have the potential to contribute to a universal, shorter, safer and simpler TB drug regimen.
  • A shorter drug regimen that can treat TB irrespective of pre-existing drug resistance could provide a significant benefit to both patients and health systems.
  • Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “We are honoured to have been awarded another grant by The Bill & Melinda Gates Foundation.
  • It is the second leading cause of death from an infectious disease worldwide and responsible for an estimated 1.6 million deaths per year.

EQS-News: Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit

Retrieved on: 
Thursday, March 16, 2023
TSX, JDRF, FSE, Cell, HSCI, ILC, GMP, PSH, Type 1 diabetes, Evotec, IPSC, Doctor of Philosophy, EVO, Pharmaceutical industry

The presentation will be given by Matthias Austen, PhD, SVP Cell Therapy at Evotec SE (FSE:EVT; NASDAQ:EVO).

Key Points: 
  • The presentation will be given by Matthias Austen, PhD, SVP Cell Therapy at Evotec SE (FSE:EVT; NASDAQ:EVO).
  • Evotec has developed a scalable and comprehensive process for GMP manufacturing of ILCs from a human GMP-grade induced pluripotent stem cell (iPSC) line for cell therapy treatment of insulin-dependent diabetes.
  • In 2022, Evotec entered into a collaboration with Sernova Corp., which has developed the proprietary Cell Pouch System™.
  • Following implantation, the Cell Pouch develops a vascularized environment to support engraftment and long-term function of therapeutic cells.

Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit

Retrieved on: 
Tuesday, March 14, 2023
TSX, JDRF, Cell, HSCI, ILC, FSE, GMP, PSH, Type 1 diabetes, Evotec, IPSC, Doctor of Philosophy, Pharmaceutical industry

The presentation will be given by Matthias Austen, PhD, SVP Cell Therapy at Evotec SE.

Key Points: 
  • The presentation will be given by Matthias Austen, PhD, SVP Cell Therapy at Evotec SE.
  • Evotec has developed a scalable and comprehensive process for GMP manufacturing of ILCs from a human GMP-grade induced pluripotent stem cell (iPSC) line for cell therapy treatment of insulin-dependent diabetes.
  • In 2022, Evotec entered into a collaboration with Sernova Corp., which has developed the proprietary Cell Pouch System™.
  • Following implantation, the Cell Pouch develops a vascularized environment to support engraftment and long-term function of therapeutic cells.

MitoRx Therapeutics Announces Scientific Advisory Board, Chief Development Officer and Finance Director

Retrieved on: 
Tuesday, March 7, 2023
Maker, GSK plc, Muscular dystrophy, University of Manchester, Therapy, Immunology, Pleasure, Royal Society, SAB, NewCo, Novartis, Neurology, Coronavirus Scientific Advisory Board, Manchester University NHS Foundation Trust, Neuromuscular disease, CDO, Glycogen storage disease, Journal of Specialised Translation, New Year Honours, Genetic distance, Consultant, Innovation, FRS, University, Nuffield Department of Population Health, Professor, Translational medicine, Royal, Keble College, Oxford, Anatomy, Government, Duchenne muscular dystrophy, AstraZeneca, Research, Scientific Advisory Group for Emergencies, NHS foundation trust, Biotechnology, Pharmaceutical industry, Management, Biology, Duchenne, Neuroscience, Child, Evotec

OXFORD, England, March 07, 2023 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing revolutionary therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces Christine Charman as Chief Development Officer, David Richardson as Finance Director, and four appointments to its Scientific Advisory Board (SAB): Prof Chas Bountra, Prof Dame Kay Davies, Prof Laurent Servais, and Dr Bernd C Schwahn.

Key Points: 
  • OXFORD, England, March 07, 2023 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing revolutionary therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces Christine Charman as Chief Development Officer, David Richardson as Finance Director, and four appointments to its Scientific Advisory Board (SAB): Prof Chas Bountra, Prof Dame Kay Davies, Prof Laurent Servais, and Dr Bernd C Schwahn.
  • He commented on his appointment: “It’s an honour and a pleasure to come together with top international scientific and clinical experts to build the MitoRx Scientific Advisory Board.
  • David Richardson BSc ACMA AMCT brings over 30 years finance experience to his new role as Finance Director.
  • Jonathan Rees PhD, CEO of MitoRx, said, “We are thrilled to welcome our new SAB members, as well as Christine Charman as Chief Development Officer and David Richardson as Finance Director, who together bring a wealth of renowned experience across financial, scientific and clinical backgrounds.

EQS-News: Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer

Retrieved on: 
Monday, February 13, 2023
Supervisory board, Financial Oversight and Management Board for Puerto Rico, Danone, Frankfurt Stock Exchange, ISIN, CFO, Coty, Building, Growth, EVO, Science, Disease, Biology, MDAX, Cosmetics, Business, Pfizer, Management, Evotec, Pharma, Food

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company's Supervisory Board has appointed Laetitia Rouxel as new Chief Financial Officer and member of the Management Board effective 01 April 2023.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company's Supervisory Board has appointed Laetitia Rouxel as new Chief Financial Officer and member of the Management Board effective 01 April 2023.
  • She will take over from Enno Spillner whose contract will expire at the end of March and who will pursue new opportunities.
  • I’m grateful for having had this unique opportunity and wish Evotec all the very best”, said Enno Spillner.
  • Laetitia Rouxel, designated Chief Financial Officer of Evotec SE, commented: “I am thrilled to join the very talented and passionate team of Evotec, a company with a strong sense of purpose to improve disease understanding through data, science and biology.

EQS-News: Enno Spillner appointed Chief Financial Officer (CFO) of Formycon AG

Retrieved on: 
Monday, February 13, 2023
Supervisory board, Head, Financial Oversight and Management Board for Puerto Rico, ISIN, WKN, Evotec, CFO, TecDAX, CSO, CBO, Communication, RTÉ Executive Board, Nanobiotix, Biome, Human resources, MDAX, AG, Management, Property management

Press Release // February 7, 2023

Key Points: 
  • Press Release // February 7, 2023
    Munich, Germany - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced that the Company's Supervisory Board has appointed Mr. Enno Spillner to the Company's Executive Board as Chief Financial Officer (CFO) effective April 1, 2023.
  • Previously, Mr. Spillner worked for more than ten years (2005-2016) at the publicly listed 4SC AG, an innovative biopharmaceutical company, where he held the position as Chief Financial Officer and later additionally as Chief Executive Officer.
  • Prior to that, Mr. Spillner had worked at Bioᴹ AG since 1999, initially as Head of Finance & Controlling.
  • "With Enno Spillner, we are gaining an experienced and outstanding manager who has worked extremely successfully for many years as Chief Financial Officer at internationally operating listed biotechnology companies.